Latest Press Releases Jun 09 2023 Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Read More Jun 09 2023 Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress Read More Jun 08 2023 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Read More May 30 2023 Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13 Read More May 03 2023 Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older Read More May 01 2023 Vertex Reports First Quarter 2023 Financial Results Read More Load More Recent Media Library Items View All Date - Any -20212022 Tags Download LibraryImages Our mRNA Investigational Therapy (VX-522) Infographic Download 9 MB Date - Any -20212022 Tags Download LibraryImages Reshma Kewalramani, M.D. Chief Executive Officer and President Download Date - Any -20212022 Tags Download LibraryImages Vertex International Headquarters Paddington – Lobby Padding reception entrance Download 915 KB Date - Any -20212022 Tags Download LibraryImages Vertex Logo with Tagline Download 2 MB | 2951 x 1952 Mediainfo@VRTX.com
Jun 09 2023 Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment With CFTR Modulators at the European Cystic Fibrosis Conference Read More
Jun 09 2023 Positive Results From Pivotal Trials of exa-cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease Presented at the 2023 Annual European Hematology Association (EHA) Congress Read More
Jun 08 2023 FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia Read More
May 30 2023 Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13 Read More
May 03 2023 Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants With CF Ages 1 Month and Older Read More
